上皮性卵巢癌患者肿瘤组织及血清中YKL-40的表达及临床意义

目的探讨甲壳质酶蛋白40（YKL-40）在上皮性卵巢肿瘤发生发展中的作用。方法 （1）免疫组化法检测20例上皮性良性卵巢肿瘤、10例交界性卵巢肿瘤及30例卵巢癌组织中YKL-40的表达情况。（2）酶联免疫吸附法检测三组患者血清中YKL-40的水平。结果 （1）YKL-40在卵巢癌组织的阳性表达率高于良性组（P〈0.05）;交界组与卵巢癌组无差异（P〉0.05）,但卵巢癌组YKL-40染色强度高于交界组（P〈0.05）;早期卵巢癌（Ⅰ、Ⅱ期）组织中阳性表达率低于晚期卵巢癌（Ⅲ、Ⅳ期）组织中阳性表达率（P〈0.05）,YKL-40组织中表达水平与卵巢癌临床分期呈正相关（P〈0.05）。（2）上皮性良性卵巢肿瘤、交界性卵巢肿瘤及卵巢癌患者中,血清YKL-40的中位数分别为41.42、44.34、130.25（μg/L）。卵巢癌组血清YKL-40水平高于前二组,差异有统计学意义（P〈0.05）,前二组比较差异无统计学意义。卵巢癌患者血清YKL-40浓度与临床分期及CA125浓度呈正相关（P〈0.05）。结论 YKL-40蛋白可能参与了卵巢肿瘤的发生发展过程。     

Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma

High grade serous ovarian carcinoma (HGSC) without identifiable serous tubal intraepithelial carcinoma (STIC) within the fallopian tube (FT) occurs in approximately 50% of patients. The objective of this study was to use a multisite tumor sampling approach to study HGSC with and without STIC. RNAseq analysis of HGSC samples collected from multiple sites e.g. ovary, FT and peritoneum, revealed moderate levels of intrapatient heterogeneity in gene expression that could influence molecular profiles. Mixed-model ANOVA analysis of gene expression in tumor samples from patients with multiple tumor sites (n = 13) and patients with a single site tumor sample (n = 11) to compare HGSC-STIC to HGSC-NOSTIC identified neurotensin (NTS) as significantly higher (> two-fold change, False Discovery Rate (FDR) < 0.10) in HGSC-STIC. This data was validated using publicly available RNA-Seq datasets. Concordance between higher NTS gene expression and NTS peptide levels in HGSC-STIC samples was demonstrated by immunohistochemistry. To determine the role of NTS in HGSC, five ovarian cancer (OvCa) cell lines were screened for expression of NTS and its receptors, NTSR1 and NTSR3. Increased expression of NTS and NSTR1 was observed in several of the OvCa cells, whereas the NTSR3 receptor was lower in all OvCa cells, compared to immortalized FT epithelial cells. Treatment with NTSR1 inhibitor (SR48692) decreased cell proliferation, but increased cell migration in OvCa cells. The effects of SR48692 were receptor mediated, since transient RNAi knockdown of NTSR1 mimicked the migratory effects and knockdown of NTSR3 mimicked the anti-proliferative effects. Further, knockdown of NTSR1 or NTSR3 was associated with acquisition of distinct morphological phenotypes, epithelial or mesenchymal, respectively. Taken together, our results reveal a difference in a biologically active pathway between HGSC with and without STIC. Furthermore, we identify neurotensin signaling as an important pathway involved in cell proliferation and epithelial–mesenchymal transition in HGSC-STIC which warrants further study as a potential therapeutic target. © 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.     

Increased immunohistochemical expression of YKL-40 in the spleen of patients with portal hypertension

YKL-40 has been identified as a growth factor in connective tissue cells and also a migration factor in vascular smooth muscle cells. To a large extent, the increase of serum YKL-40 is attributed to liver fibrosis and asthma. However, the relationship of the expression and clinical/prognostic significance of YKL-40 to the splenomegaly of patients with portal hypertension is unclear. In the present study, the expression of YKL-40 was studied by immunohistochemistry in 48 splenomegaly tissue samples from patients with portal hypertension and in 14 normal spleen specimens. All specimens were quickly stored at -80°C after resection. Primary antibodies YKL-40 (1:150 dilution, rabbit polyclonal IgG) and MMP-9 (1:200 dilution, rabbit monoclonal IgG) and antirabbit immunoglobulins (HRP K4010) were used in this study. The relationship of clinicopathologic features with YKL-40 is presented. The expression of YKL-40 indicated by increased immunochemical reactivity was significantly up-regulated in splenomegaly tissues compared to normal spleen tissues. Overexpression of YKL-40 was found in 68.8% of splenomegaly tissues and was significantly associated with Child-Pugh classification (P = 0.000), free portal pressure (correlation coefficient = 0.499, P < 0.01) and spleen fibrosis (correlation coefficient = 0.857, P < 0.01). Further study showed a significant correlation between YKL-40 and MMP-9 (correlation coefficient = -0.839, P < 0.01), indicating that YKL-40 might be an accelerator of spleen tissue remodeling by inhibiting the expression of MMP-9. In conclusion, YKL-40 is an important factor involved in the remodeling of spleen tissue of portal hypertension patients and can be used as a therapeutic target for splenomegaly.     

卵巢浆液性腺癌组织中TK1和Ki-67表达的意义

目的探讨细胞质胸苷激酶1(cytoplasmic thymidinekinas-1,TK1)、Ki-67在卵巢浆液性腺癌中表达的意义。方法回顾性研究55例经手术治疗的卵巢浆液性腺癌患者的临床病理资料,并运用免疫组化技术观察TK1、Ki-67在卵巢浆液性腺癌中的表达情况及与临床病理参数之间的意义。结果 TK1阳性表达定位于细胞质,阳性率为72.7%。TK1的表达与肿瘤的最大径、复发、pTNM分期、病理分级密切相关(P<0.05)。Ki-67阳性表达定位于细胞核,阳性率为80.0%,Ki-67的表达与肿瘤的复发、pTNM分期、病理分级有关(P<0.05)。Kappa检验显示TK1的表达与卵巢浆液性腺癌复发较一致(k=0.559,P=0.000),且判断复发比Ki-67更为优越。Kaplan-Meier检验显示pTNM分期、肿瘤复发、MDACC分级、Ki-67、TK1表达分别与预后有关(P<0.05)。COX回归多因素分析显示:肿瘤复发是影响卵巢浆液性腺癌患者的独立性预后因素。结论卵巢浆液性腺癌的复发影响患者的预后,TK1对判断卵巢浆液性腺癌是否有复发倾向具有参考价值,且优于Ki-67,初次手术后肿瘤组织免疫组化T...     

急性脑梗死患者血清YKL-40检测的临床意义

目的通过检测急性脑梗死患者发病后48h内血清YKL-40的表达量,探讨其与牛津郡社区卒中项目（OCSP）分型及梗死面积大小的关系,以指导临床诊治。方法对54例急性脑梗死患者和20例正常对照者进行血清YKL-40的检测,然后分析其与病情程度及临床分型的关系。结果急性脑梗死患者血清YKL-40浓度中位数为158.47ng/ml（IR：182.40）,正常对照组为50.50ng/ml（IR：34.85）,两组比较差异有统计学意义（P〈0.001）;OCSP各亚型YKL-40升高幅度不同,完全前循环梗死（TACI）型表达量明显高于其他亚型（P〈0.01）;YKL-40在大梗死型的含量显著高于其他亚型（P〈0.02）。结论脑梗死后血清YKL-40水平升高,与病灶大小相关,在不同OCSP分型之间表达量不同,血清YKL-40可能成为指导脑梗死临床分型及评估病情程度的新的生物学指标。     

A study detection of the ROS1 gene fusion by FISH and ROS1 protein expression by IHC methods in patients with ovarian malignant or borderline serous tumors

Objective

ROS1 is an orphan receptor protein tyrosine kinase which is supposed to undergo genetic rearrangement in carcinogenesis. In the current study, we aimed to investigate the frequency and clinicopathologic features associated with ROS1 gene fusion and ROS1 protein expression in patients with ovarian serous carcinoma or serous borderline tumors.

血清YKL-40蛋白水平与非肌层浸润性膀胱癌复发的临床关系研究

目的:探讨患者血清YKL-40蛋白水平与非肌层浸润性膀胱癌(non muscle-invasive bladder cancer, NMIBC)复发的临床关系.方法:选取76例NMIBC患者,其中34例为术后随访两年内确诊复发患者、42例为术后随访两年未见复发患者,及健康对照组31例,采取清晨血清样本,采用酶联接免疫吸附剂测定法(ELISA)检测患者血清中YKL-40水平.结果:NMIBC患者血清YKL-40水平显著高于健康对照组(P<0.001),同时,NMIBC复发组患者血清YKL-40水平高于非复发组(P=0.001).结论:血清YKL-40蛋白水平在非肌层浸润性膀胱癌复发中有着较高的临床诊断价值,可作为监测患者术后复发的一种新分子标志物,为患者术后相关后续治疗提供参考.     

Clinicopathological significance of DEK overexpression in serous ovarian tumors

To investigate the significance of DEK protein expression in ovarian lesions, a total of 113 ovarian serous tumors, including 62 serous cystadenocarcinomas and 19 serous borderline tumors, were studied on immunohistochemistry. For comparison, 32 benign serous tumors, including 12 serous papillary cystadenomas, 10 serous cystadenomas, and 10 serous surface papillomas, were also included. DEK was positive in 93.5% of serous cystadenocarcinomas (58/62), 63.2% of serous borderline tumors (12/19), and weakly positive in 15.6% of benign serous tumors (5/32). The strong positive signal was detected only in serous adenocarcinomas (80.6%, 50/62) and borderline tumors (21.1%, 4/19), but no serous benign tumors were strongly positive (0%, 0/32). Meanwhile, the strong positivity rate of DEK protein was significantly higher in grade 2 and grade 3 than in grade 1 ovarian cancers ( P < 0.05), but there was no significant association between DEK protein expression level and International Federation of Gynecology and Obstetrics (FIGO) stage of serous ovarian adenocarcinoma ( P > 0.05). In summary, DEK plays an important role in the progression of ovarian serous cancers. The detection of DEK protein expression should be useful for the diagnosis and prognosis of ovarian serous cancers, and DEK might be a useful molecular target for ovarian cancer therapy.     

卵巢浆液性肿瘤中MCM4与Ki-67的表达及意义

目的 探讨微小染色体维持蛋白4(minichromosome maintenance proteins 4,MCM4)、Ki-67在卵巢浆液性肿瘤中的表达及意义.方法 采用免疫组化EliVision两步法检测MCM4、Ki-67蛋白在10例正常卵巢上皮组织(对照组)、19例卵巢良性浆液性嚢腺瘤、16例交界性浆液性肿瘤和43例浆液性腺癌中的表达.结果 MCM4在对照组、卵巢良性浆液性囊腺瘤、交界性浆液性肿瘤、浆液性腺癌的阳性表达率分别为10.00%、21.05%、43.75%、79.07%,Ki-67在对照组、卵巢浆液性乳头状腺瘤、交界性嚢腺瘤、浆液性腺癌的阳性表达率分别为10.00%、15.79%、25.00%、53.49%,其随着卵巢肿瘤病变的升级呈增高的趋势.MCM4在卵巢浆液性腺癌和交界性浆液性肿瘤中的表达与正常对照组相比差异具有统计学意义(P<0.05).Ki-67在卵巢浆液性癌和交界性浆液性肿瘤中的表达与正常对照组相比差异具有统计学意义(P<0.05).MCM4在卵巢浆液性癌中的表达与临床分期、病理分级及转移[淋巴结转移和(或)器官转移]有明显相关(P<0.05).Ki-67蛋白在卵巢浆液性癌中的表达与病理分级及淋巴结转移有明显相关(P<0.05),MCM4和Ki-67呈正相关.结论 MCM4、Ki-67为卵巢浆液性肿瘤的增殖指标,用于卵巢良、恶性肿瘤的鉴别和诊断,并可初步评估肿瘤预后,指导临床治疗.     

Overexpression of YKL-40 is an independent prognostic marker in gastric cancer

YKL-40 is a growth factor for connective tissue cells and a migration factor for endothelial cells. Elevated serum level of YKL-40 has been associated with poor prognosis in many cancers. However, the status of YKL-40 expression and its clinical/prognostic significance in gastric cancer are unclear. In this study, the expression of YKL-40 was studied by immunohistochemistry in gastric cancer tissue microarray containing 172 primary gastric cancer cases and 70 adjacent nonneoplastic mucosa specimens. The correlations between YKL-40 expression and clinicopathologic features, as well as activation of PI3K/Akt pathways were addressed. Expression of YKL-40 was significantly higher in gastric cancer tissues than that in adjacent nonneoplastic tissues. Overexpression YKL-40 was found in 28.4% of gastric cancers and was significantly associated with tumor invasion (P = .007) and lymph node metastasis (P = .009). For survival study, overexpression of YKL-40 was significantly associated with worse outcome (P = .001). When known clinical variables were added to a multivariate analysis, TNM stage, tumor size, and overexpression of YKL-40 emerged as independent prognostic factors. Further study indicated that the oncogenic function of YKL-40 might be through the activation of Akt pathway. These results suggest that overexpression of YKL-40 is correlated with the aggressive behavior of tumor cells, which could be used as an independent molecular marker for the predicting poor prognosis of patients with gastric cancer.     

血清YKL-40对非酒精性脂肪肝肝纤维化的预测作用

目的探讨非酒精性脂肪肝患者血清中YKL-40水平及在肝纤维化程度评价中的价值。方法2017年7月至2019年7月于我院就诊的NAFLD患者142例,根据是否发生肝纤维化分为纤维化组(n=60)与非纤维化组(n=82),另纳入40例健康体检者作为健康对照组,采用放射免疫分析法测定血清中透明质酸(HA)、III型前胶原(PC III)、IV型胶原(CIV)及层粘连蛋白(LN)水平。采用双夹心抗体ELISA法检测血清YKL-40水平。结果三组研究对象年龄、性别、BMI指数等一般性资料差异无统计学意义(P>0.05);健康对照组、S0~S4期血清YKL-40水平随着肝纤维化分期的不断增加而不断升高(P<0.05)。血清YKL-40水平与NFS、FIB-4、APRI评分均呈显著正相关关系,具有统计学意义(P<0.05)。ROC分析结果表明,当Cutoff值为158 ng/mL时,YKL-40对NAFLD患者肝纤维化诊断价值最高,其AUC、灵敏度、特异性、PPV、NPV等均高于传统肝纤维化指标,差异具有统计学意义(P<0.05)。结论血清YKL-40在非酒精性脂肪肝患者中水平明显升高,对肝纤维化具有良好的预测价值。     

Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis

Early serous carcinoma in fallopian tube or serous tubal intraepithelial carcinoma (STIC), an early lesion limited to the epithelium of the fallopian tube and firstly identified from specimen obtained by prophylactic salpingo-oophorectomy, has provided insight into pelvic high grade serous carcinoma (HGSC). Increasing evidence indicates that STIC is a likely precursor for HGSC and several studies have focused on this lesion and its clinical significance. This review addresses recent advances in recognizing STIC and its correlation with HGSC and ovarian carcinogenesis. It also describes evidence regarding the fallopian tube as a source of some HGSCs, the protocol for optimizing histological evaluation of the tubes, the spectrum of tubal lesions from benign to noninvasive carcinoma, changes in diagnostic criteria from purely morphologic characteristics to a combination of morphologic features and molecular biomarkers, and new studies about potential biomarkers. However, the direct evidence regarding STIC as the precursor of HGSC is still tantalizing due to other possibilities that may also explain the origin of pelvic HGSC. Further molecular genetic studies are required to address this important question.     

双抗体夹心法测定血清YKL-40在肝硬化中的诊断价值研究

探讨肝硬化(liver cirrhosis,LC)患者外周血中血清YKL-40(壳多糖酶3样蛋白1)蛋白水平及其在LC中的诊断意义。采用ELISA方法共检测112例LC患者以及114例健康者血清中YKL-40蛋白水平,并进一步分析其在LC中的诊断价值及其与LC患者肝功能和现有肝纤维化指标的相关性。LC组血清YKL-40蛋白水平高于正常对照组(P0.001);将LC组和对照组作比较,ROC曲线分析血清YKL-40蛋白对LC的诊断效能,曲线下面积(area under the curve,AUC)为0.934(95%置信区间为:0.904~0.964),YKL-40在cutoff值为92.25ng/mL时,敏感度为81.3%,特异度为90.4%;通过相关性分析发现血清YKL-40蛋白水平与肝功能Child-Pugh分级和FIB-4指数正相关。YKL-40对LC具有良好的诊断效力,能辅助诊断LC并有助于判断LC的严重程度。     

Assessment of the argyrophilic nucleolar organizer region area/nucleus ratio in ovarian serous epithelial adenomas,borderline tumors and cancers

Introduction

There is a need to assess the value of the novel potentially useful biomarkers in ovarian tumors. The aim of study was to assess the value of sAgNOR analysis in ovarian serous epithelial tumors.

Material and methods

The analysis was performed in ovaries from 113 patients treated operatively due to serous ovarian tumors (30 adenomas, 14 borderline tumors and 69 cancers). After silver staining of paraffin specimens from surgery, sAgNOR in tumor cells was analyzed. Additionally, the value of the argyrophilic nucleolar organizer region area/nucleus ratio (sAgNOR) in the prediction of disease-free survival (DFS) and overall survival (OS) in 52 patients with serous ovarian cancer with complete follow-ups in November 2009 was evaluated. Age, grading, radicality of surgery and FIGO staging were analyzed as additional factors.

Results

sAgNOR in adenomas, borderline tumors and cancers was in the following ranges: (0.73 ±0.23) × 10⁶, (0.81 ±0.18) × 10⁶ and (0.96 ±0.33) × 10⁶ [AgNOR/cm²] respectively. In cancers from G1 to G3 sAgNOR was (1.02 ±0.32) × 10⁶ (G1), (0.98 ±0.37) × 10⁶ (G2) and (0.82 ±0.24) × 10⁶ (G3) [AgNOR/cm²] respectively. In univariate analysis, but not in multivariate analysis, staging negatively correlated with better DFS and OS. sAgNOR, age of patients, grading and radicality of surgery were not associated with DFS or OS in either univariate or multivariate analysis.

Conclusions

sAgNOR analysis is not sufficient to precisely characterize cellular kinetics in serous ovarian tumors, and the analysis of sAgNOR, mAgNOR and pAgNOR should be performed commonly. The prognostic significance of sAgNOR in patients with serous ovarian cancer was not proven.     

卵巢浆液性交界性肿瘤中clusterin的表达

目的探讨凋亡抑制因子clusterin在卵巢浆液性肿瘤中发生、发展的作用及其与bcl-2、Ki-67表达的关系。方法免疫组化sP法检测clusterin、bcl-2、Ki-67在20例卵巢浆液性囊腺瘤,28例浆液性交界性肿瘤,26例浆液性囊腺癌标本中的表达。结果clusterin在囊腺瘤、交界性肿瘤、囊腺癌中的阳性率分别为40％,67．9％,96．2％。囊腺癌中的clusterin与Ki-67的表达水平均明显高于囊腺瘤（P〈0．05）和SBOT（P〈0．05）。交界性肿瘤中有腹水的患者clusterin阳性率要明显高于无腹水者（P=0．0390）,Ki-67在有腹膜种植的患者阳性率要明显高于无腹膜种植者（P=0．0473）。且两者的表达成正相关。结论clusterin基因可能通过抑制凋亡在卵巢浆液性肿瘤的发生发展中起重要作用。clusterin与Ki-67结合起来分析可能作为鉴别SBOT与浆液性癌的辅助指标。     

Distinct evolutionary trajectories of primary high‐grade serous ovarian cancers revealed through spatial mutational profiling

High‐grade serous ovarian cancer (HGSC) is characterized by poor outcome, often attributed to the emergence of treatment‐resistant subclones. We sought to measure the degree of genomic diversity within primary, untreated HGSCs to examine the natural state of tumour evolution prior to therapy. We performed exome sequencing, copy number analysis, targeted amplicon deep sequencing and gene expression profiling on 31 spatially and temporally separated HGSC tumour specimens (six patients), including ovarian masses, distant metastases and fallopian tube lesions. We found widespread intratumoural variation in mutation, copy number and gene expression profiles, with key driver alterations in genes present in only a subset of samples (eg PIK3CA, CTNNB1, NF1). On average, only 51.5% of mutations were present in every sample of a given case (range 10.2–91.4%), with TP53 as the only somatic mutation consistently present in all samples. Complex segmental aneuploidies, such as whole‐genome doubling, were present in a subset of samples from the same individual, with divergent copy number changes segregating independently of point mutation acquisition. Reconstruction of evolutionary histories showed one patient with mixed HGSC and endometrioid histology, with common aetiologic origin in the fallopian tube and subsequent selection of different driver mutations in the histologically distinct samples. In this patient, we observed mixed cell populations in the early fallopian tube lesion, indicating that diversity arises at early stages of tumourigenesis. Our results revealed that HGSCs exhibit highly individual evolutionary trajectories and diverse genomic tapestries prior to therapy, exposing an essential biological characteristic to inform future design of personalized therapeutic solutions and investigation of drug‐resistance mechanisms. © 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.     

血浆YKL-40浓度对危重症患者并发腹腔间隙综合征的预测作用

目的:揭示危重症患者血浆YKL-40浓度的变化,探讨其对危重症患者并发腹腔间隙综合征的预测价值。方法:收集危重症患者和健康体检人群各98例。健康体检人群静脉血体检时获得,危重症患者静脉血在入院时获得。ELISA检测血浆YKL-40浓度。结果:危重症患者血浆YKL-40浓度(146.8±79.5)ng/ml显著高于健康体检者(39.4±12.5)ng/ml(t=8.749,P<0.01),与APACHEⅡ评分,呈显著正相关性(r=0.591,P<0.01)。28例(28.6%)并发腹腔间隙综合征。多因素分析显示,血浆YKL-40浓度(OR=1.492,95%CI=1.231～2.116,P<0.01)是危重症患者并发腹腔间隙综合征的独立危险因素。ROC曲线分析显示,血浆YKL-40浓度预测危重症患者并发腹腔间隙综合征有显著预测价值(曲线下面积=0.842,95%CI=0.791～0.914,P<0.001),且判定血浆YKL-40浓度>172.4 ng/ml,对预测并发腹腔间隙综合征有82.1%的灵敏度和78.6%的特异度。结论:危重症患者并发腹腔间隙综合征后,血浆YKL-40浓度显著升高,临床检测YKL-40作为有预报价值的标志物,有助于早期判断腹腔间隙综合征的发生。     

血清YKL-40和CA125联合检测在卵巢癌诊断中的应用

目的探讨血清YKL-40和CA125联合检测在卵巢癌诊断中的应用价值。方法分别用酶免分析法（EIA）和微粒子酶免分析法（MEIA）测定39例卵巢癌、27例卵巢良性肿瘤及40例健康对照妇女血清YKL-40和CA125水平,YKL-40以健康对照组95％可信区间的上限值为阳性,比较YKL-40和CA125在三组间、卵巢癌病人不同临床分期和手术治疗前后水平和阳性率的差异。结果正常对照组血清YKL-40水平的95％可信区间的上限值为71．9ng／mL;卵巢癌患者血清YKL-40水平及阳性率显著高于卵巢良性肿瘤组和对照组（t〉4．83,P〈0．01）,而卵巢良性肿瘤组和对照组之间差异无统计学意义（t=0．96,P〉0．05）。Ⅲ／Ⅳ期卵巢癌患者血清YKL-40水平显著高于Ⅰ／Ⅱ期患者（167．9ng／mL vs 87．7ng／mL,t=1．86,P〈0．01）。卵巢癌患者术后第3天和第7天血清YKL-40水平显著低于术前水平（t〉2．92,P〈0．01）;未能手术切除的患者血清YKL-40水平显著高于手术切除者（t=4．06,P〈0．01）。YKL-40联合CA125诊断卵巢癌的灵敏度为87．2％,特异性为91．0％,阳性预测值为85．0％,阴性预测值为92.4％;YKL-40与CA125联合诊断早期卵巢癌的灵敏度从CA125单指标的33．3％提高到66．7％。结论YKL-40是一种新的诊断卵巢癌的肿瘤标志物,联合YKL-40与CA125检测可提高对早期卵巢癌诊断的灵敏度。     

Ki-67抗原和Survivin基因在上皮性卵巢癌中表达增强且相关

目的探讨卵巢上皮性肿瘤中Ki-67抗原和Survivin的表达及其相关性。方法用免疫组织化学技术二步法检测47例上皮性卵巢癌和24例良性上皮性卵巢肿瘤中Ki-67抗原和Survivin的表达。结果Ki-67阳性染色位于细胞核,良性肿瘤中Ki-67指数为0.17±0.20,显著低于恶性的19.59±16.48(P<0.01)。Survivin在良性卵巢肿瘤中的表达率为33.33%,显著低于恶性的70.21%(P<0.01)。Ki-67和Survivin在上皮性卵巢癌中的表达均与组织学类型无关,而与临床分期及病理学分级密切相关(P<0.01)。Ki-67和Survivin的表达有相关性。结论Ki-67和Sur-vivin基因在卵巢癌中表达增强且相关。